Results 41 to 50 of about 9,288,830 (350)
Patients taking adjuvant endocrine therapy (AET) after breast cancer face adherence challenges and symptom‐related distress. We conducted a randomized trial to evaluate the feasibility, acceptability, and preliminary efficacy of a telehealth intervention
Jamie M. Jacobs +14 more
semanticscholar +1 more source
Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common ...
Jing Chen +6 more
doaj +1 more source
Mechanisms of Endocrine Therapy Resistance in Breast Cancer.
The most commonly diagnosed breast cancer (BC) subtype is characterized by estrogen receptor (ER) expression. Treatment of this BC subtype typically involves modalities that either suppress the production of estrogen or impede the binding of estrogen to ...
F. Rasha, Monica Sharma, K. Pruitt
semanticscholar +1 more source
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo +2 more
core +1 more source
Pig islets demonstrate significantly lower insulin secretion after glucose stimulation than human islets (stimulation index of ~12 vs. 2 for glucose 1 and 15 mM, respectively) due to a major difference in β- and α-cell composition in islets (60% and 25 ...
Sophie Vériter +5 more
doaj +1 more source
Ki67 is a proliferation marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response.
Ai-Lin Zhang +3 more
semanticscholar +1 more source
Interactions between chemotherapy, endocrine therapy and radiation [PDF]
In an investigation by the Swedish Cancer Society, an expert group described the present status, critical issues and future aspects and potentials for each of nine major areas of radiation therapy research.
Kjellén, Elisabeth, +5 more
core +3 more sources
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj +1 more source
The immunomodulatory effects of endocrine therapy in breast cancer
Endocrine therapies with SERMs (selective estrogen receptor modulators) or SERDs (selective estrogen receptor downregulators) are standard therapies for patients with estrogen receptor (ER)-positive breast cancer.
Huanhuan Huang +6 more
semanticscholar +1 more source
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
BACKGROUND The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early‐stage, estrogen‐receptor (ER)–positive breast cancer.
H. Pan +10 more
semanticscholar +1 more source

